Back to Agenda
Session 8 : Panel Discussion | Decentralized Clinical Trials (DCT): Improving the patient experience and accelerating clinical trials using a decentralized approach
Session Chair(s)
Shobhit Shrotriya, PMP
Managing Director, Life Sciences R&D Operations, India
Accenture, India
Patient centricity and patient experience has been one of the core factors while addressing patient retention in clinical trials. The pandemic has further made us realize that there is an urgency to accelerate trial design and execution, thereby reimagining how clinical trials are run. By putting patients at the center, decentralization makes participating in a clinical trial more seamless and convenient, thereby enabling cost optimization and at the same time improving the patient experience. Pharmaceutical organizations, sites, investigators and patients have all started to see the benefits of decentralized clinical trials that will in future become the new industry norm. Remote or decentralized clinical trials includes an operational strategy for technology enablement that is more accessible to the patients. This is an immense opportunity for pharmaceutical organizations to embrace the change and focus on how the clinical trials can be delivered moving forward.
Speaker(s)
Contributing Panelist
Niraj Vyas
The Janssen Pharmaceutical Companies of Johnson & Johnson, India
Director Risk Management & Central Monitoring
Contributing Panelist
Esther Ninan
Novartis, India
Director, Clinical Data Management
Contributing Panelist
Ram Mudaliar
AstraZeneca, India
Senior Director (India CDI Lead) Clinical Data & Insights (CDI)
Have an account?